Moreover, it is important to note that animal models may not necessarily be directly applicable to humans, and more clinical trials are needed to fully evaluate the potential benefits and risks of GH and IGF-1 therapy in managing obesity. This evidence concerns the gene IGF1 and obesity due to melanocortin 4 receptor deficiency.